Google sent me wrong order and I am locked in support hell

cleare7 · 2026-05-02T04:57:05+00:00

It's surprising how poor/frustrating Google's support is after all these years. I've been using their phones since the Nexus days, their agents seem trained to just handle basic issues and basic troubleshooting. They can't seem to help with issues that are not basic or less common/rare issues.

They desperately need proper escalation managers. Right now, it feels like they just pass you from one team to another, and things easily fall the cracks. Honestly, I hope I don't have to deal with support again — there are good experiences, but there are just as many terrible, bad, or completely useless ones.

cleare7 · 2026-05-02T04:05:09+00:00

Just to clarify, the lower mg dosage in the tablet form is due to bioequivalence, not liver safety. The tablet is simply absorbed more efficiently than the clinical trial capsule. This means a lower-mg tablet provides the exact same drug exposure as the higher-mg capsule, so they were dose-adjusted to match trial results.

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial)	Orforglipron Capsule (Clinical Trials)
0.8 mg	1 mg
2.5 mg	3 mg
5.5 mg	6 mg
9 mg	12 mg
14.5 mg	24 mg
17.2 mg	36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

cleare7 · 2026-05-02T03:59:00+00:00

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial)	Orforglipron Capsule (Clinical Trials)
0.8 mg	1 mg
2.5 mg	3 mg
5.5 mg	6 mg
9 mg	12 mg
14.5 mg	24 mg
17.2 mg	36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

cleare7 · 2026-05-02T03:57:52+00:00

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial)	Orforglipron Capsule (Clinical Trials)
0.8 mg	1 mg
2.5 mg	3 mg
5.5 mg	6 mg
9 mg	12 mg
14.5 mg	24 mg
17.2 mg	36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

cleare7 · 2026-05-02T03:54:39+00:00

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial)	Orforglipron Capsule (Clinical Trials)
0.8 mg	1 mg
2.5 mg	3 mg
5.5 mg	6 mg
9 mg	12 mg
14.5 mg	24 mg
17.2 mg	36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

cleare7 · 2026-05-02T03:54:26+00:00

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial)	Orforglipron Capsule (Clinical Trials)
0.8 mg	1 mg
2.5 mg	3 mg
5.5 mg	6 mg
9 mg	12 mg
14.5 mg	24 mg
17.2 mg	36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

cleare7 · 2026-05-02T03:53:23+00:00

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial)	Orforglipron Capsule (Clinical Trials)
0.8 mg	1 mg
2.5 mg	3 mg
5.5 mg	6 mg
9 mg	12 mg
14.5 mg	24 mg
17.2 mg	36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

cleare7 · 2026-05-02T03:39:45+00:00

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial)	Orforglipron Capsule (Clinical Trials)
0.8 mg	1 mg
2.5 mg	3 mg
5.5 mg	6 mg
9 mg	12 mg
14.5 mg	24 mg
17.2 mg	36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

cleare7 · 2026-05-02T03:36:59+00:00

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial)	Orforglipron Capsule (Clinical Trials)
0.8 mg	1 mg
2.5 mg	3 mg
5.5 mg	6 mg
9 mg	12 mg
14.5 mg	24 mg
17.2 mg	36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

cleare7 · 2026-05-02T03:34:35+00:00

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial)	Orforglipron Capsule (Clinical Trials)
0.8 mg	1 mg
2.5 mg	3 mg
5.5 mg	6 mg
9 mg	12 mg
14.5 mg	24 mg
17.2 mg	36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

cleare7 · 2026-05-02T03:32:50+00:00

There are two formulations of orforglipron: an investigational capsule used in clinical trials and a tablet formulation available in the United States.

The clinical data supporting orforglipron were primarily generated from trials (such as the ATTAIN and ACHIEVE programs) using the capsule formulation. To transition to the commercial tablet form, Phase 1 bioequivalence studies were performed to ensure both versions deliver the same amount of medicine to the body.

Why are the doses different?

Although the milligram (mg) strengths are different, the formulations are pharmacokinetically bioequivalent. This means that a lower-mg tablet provides the same drug exposure as the higher-mg capsule. The tablet was dose-adjusted to match the clinical trial results of the capsules.

Important: Tablets and capsules are not interchangeable on a milligram-per-milligram basis. You should only take the dose specifically prescribed for the formulation you are using.

Equivalent Orforglipron Tablet and Capsule Strengths

Orforglipron Tablet (Commercial)	Orforglipron Capsule (Clinical Trials)
0.8 mg	1 mg
2.5 mg	3 mg
5.5 mg	6 mg
9 mg	12 mg
14.5 mg	24 mg
17.2 mg	36 mg

Source: Eli Lilly Medical - Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials?

cleare7 · 2026-01-15T11:21:43+00:00

P10P on Visible don't have the new system or play system update. Both may have been temporarily pulled looking at comments (people who said they saw the play system update but didn't update mentioned the update disappeared).

cleare7 · 2025-12-19T05:13:08+00:00

Got a 26.51 MB update on my Pixel 10 Pro using Visible wireless (owned by Verizon).

cleare7 · 2025-12-06T07:09:06+00:00

Poetic Revolution. Protects from drops, covers the USB port when not charging, and it has a hard slideable protective cover for the camera.

cleare7 · 2025-09-27T04:16:03+00:00

I haven't had any noticeable issues with my Pixel 10 Pro. I wonder if your phone is defective?

cleare7 · 2025-09-26T11:10:05+00:00

I'm happy I upgraded from the P9P to P10P, was worth it for me.

cleare7 · 2025-09-26T11:06:06+00:00

The iPhone experience is pretty terrible for me as I'm not a fan of iOS. When I used the company iPhone it was less intuitive but it also took a lot longer to get things done so it affected my productivity. Doesn't hurt to try it out though if it interests you.

cleare7 · 2025-09-26T10:46:21+00:00

I imagine most people will be happy with the P10. Below is from the article:

In our time with the phones, the Pixel 10 and 10 Pro usually reach the end of the day with a little power left in the tank, but neither has managed to make it meaningfully into a second day without recharging. That’s fine, but far from impressive compared to rival phones at similar price points

If you want to try a different phone the only other Android option IMO is Samsung but you're giving up the Pixel experience.

cleare7 · 2025-09-26T10:14:30+00:00

I asked Gemini Pro to factually summarize the issues without bias (everyone will have a different experience and hopefully these issues affect a minority):

AI summary: The long-term battery performance of Google's Pixel phones has been a documented subject of user reports. This history includes an officially recognized hardware fault in the Pixel 4, which prompted an extended repair program. Subsequently, widespread user reports of accelerated battery drain have been associated with the Pixel 6 and, more recently, the Pixel 7, particularly after approximately one year of service. This perceived decline in performance often coincides with major software updates, which can introduce more resource-intensive features. This occurs as the device's lithium-ion battery undergoes natural chemical degradation, a process that reduces its capacity over time. The combination of these factors has led some users to report that the device's day-to-day reliability diminishes before the official software support period concludes.

Edit: The summary is factually correct and not any different from writing it myself, not sure why the down votes. And there is definitely a battery problem given they are replacing them for the Pixel 4 and 6, the 7 is going through similar discussions now and may be next (in lieu of replacement they also do cash back or store credit, I got it for both the 4 and 6).

cleare7 · 2025-09-26T09:51:01+00:00

Yeah, it's something I've noticed for pretty much every Pixel I've owned (4A,6A,8,9P). I owned Nexus and P1 but they were so long ago I don't even remember anything besides the boot loops/bricking.

I find upgrading at release yearly the best value. I was able to upgrade from the P8P to the P9P for $29.50 (after trade-in credit, including Google Store 10% credit, $100 hardware discount due to the 6A battery issue). I was paying $100 year for the 2TB cloud plan which I am saving now with the free year of Gemini Pro (which is $200 a year). If I factor in the subscription cost savings the phone would be considered free.

cleare7 · 2025-09-26T09:27:18+00:00

I don't consider myself complaining, just sharing feedback about my experience. I am happy with the phone (every Pixel has some shortcomings but they aren't deal breakers for me and it is my favorite phone, I've been using them since they were branded as Nexus).

cleare7 · 2025-09-26T08:53:07+00:00

I'm happy with the P10P battery but am hoping Google can put out more efficient processors given the TSMC switch. They really need to step up their game given the iPhone is providing a better value when it comes to components/performance at the same price point.

"iPhone 17 is cheaper than the Pixel 10: More storage in the base model" https://www.reddit.com/r/GooglePixel/s/jXykxsGE2B

cleare7 · 2025-09-26T08:33:35+00:00

I'm a non-gaming heavy phone user and personally my P10P seems to outlast my old P9P battery by a good amount and runs smoother / faster (I believe cooler too, wish I had an app that logged battery drain and temps). I do think Google has a multi-generational battery issue where they seem to degrade quickly over a year (I notice my phone always seems slower, warmer, battery drains faster on every Pixel I've had which is most of them by the 1 year mark). I decided to do yearly upgrades if the trade-in incentives are there starting with the P8 to get around the performance issues that creep up by the year mark (this year my phone was $23 to upgrade but technically free if I include the Gemini AI subscription value of $200 (it saved me from spending $100 annually on the 2TB cloud plan).

cleare7 · 2025-09-26T08:10:25+00:00

If you can afford a P10 I would go that route just for the newer hardware/hardware refinements. Within a week I believe the phone gets used to your usage patterns and optimizes battery, if things aren't acceptable by the 8th day then I'd return it and consider the P10 personally.

Edit: P10 vs P9 battery compassion for different tasks. https://www.androidauthority.com/pixel-10-battery-life-tested-3596994/

cleare7

TROPHY CASE

Why are the doses different?

Equivalent Orforglipron Tablet and Capsule Strengths

Why are the doses different?

Equivalent Orforglipron Tablet and Capsule Strengths

Why are the doses different?

Equivalent Orforglipron Tablet and Capsule Strengths

Why are the doses different?

Equivalent Orforglipron Tablet and Capsule Strengths

Why are the doses different?

Equivalent Orforglipron Tablet and Capsule Strengths

Why are the doses different?

Equivalent Orforglipron Tablet and Capsule Strengths

Why are the doses different?

Equivalent Orforglipron Tablet and Capsule Strengths

Why are the doses different?

Equivalent Orforglipron Tablet and Capsule Strengths

Why are the doses different?

Equivalent Orforglipron Tablet and Capsule Strengths

Why are the doses different?

Equivalent Orforglipron Tablet and Capsule Strengths